Username

Password

Forgot Password?

Preview

Sign-in free and Explore the Exciting World of BiomedExperts:

Over 1.500.000 Profiles
More than 1.800 Organizations worldwide
State of the Art Network Visualizations

Manage your own Profile
Locate Experts in your Country/Region
Locate Experts in your 1. and 2. Level Network
Connect to Experts Worldwide

NetworkView

Patrick Robberecht

This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles free of charge to researchers worldwide.

Research Profile (preview)

Chemicals & Drugs

Anatomy

Living Beings

Concepts & Ideas

Molecular Sequence Data

Genes & Molecular Sequences

Amino Acid Sequence

Physiology

Sign-in to see full Profile

Network (preview)

Co-Publications
Name
70
De Neef, Philippe
55
Waelbroeck, Magali
46
Gourlet, P
33
Vandermeers, A
32
Vertongen, Pascale
30
Vandermeers-Piret, MC
22
Langer, Ingrid
14
Perret, Jason
12
Svoboda, Michal
11
Cnudde, Johnny
10
Di Paolo, E
9
Delporte, Christine
9
Juarranz, María
9
Tastenoy, Michèle
9
Van Rampelbergh, J

Sign-in to see all Coauthors

Publications

TOP 3
Langer Ingrid; Leroy Karelle; Gaspard Nathalie; Brion Jean-Pierre; Robberecht Patrick
Cell surface targeting of VPAC1 receptors: evidence for implication of a quality control system and the proteasome.
de Maria Salvatore; Metafora Vittoria; Metafora Salvatore; Ravagnan Gianpietro; Cartení Maria; Pontoni Gabriele; Facchiano Angelo; Lepretti Marilena; Severino Beatrice; Caliendo Giuseppe; Santagada Vincenzo; Langer Ingrid; Robberecht Patrick
Effect of positive charge in VIP 16gamma-glutamyl diamino derivatives on hVPAC1 and hVPAC2 receptor function.
Langer I; Robberecht P
Molecular mechanisms involved in vasoactive intestinal peptide receptor activation and regulation: current knowledge, similarities to and differences from the A family of G-protein-coupled receptors.

Sign-in to see all Publications

Sign in free and see...

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the visualized research activity
of experts around the globe

Sign-in to see more

Geonetwork of Patrick Robberecht (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Sign-in to see more

All Publications

2008: Langer Ingrid; Leroy Karelle; Gaspard Nathalie; Brion Jean-Pierre; Robberecht Patrick
Cell surface targeting of VPAC1 receptors: evidence for implication of a quality control system and the proteasome.
Biochimica et biophysica acta 2008;1783(9):1663-72.
2008: de Maria Salvatore; Metafora Vittoria; Metafora Salvatore; Ravagnan Gianpietro; Cartení Maria; Pontoni Gabriele; Facchiano Angelo; Lepretti Marilena; Severino Beatrice; Caliendo Giuseppe; Santagada Vincenzo; Langer Ingrid; Robberecht Patrick
Effect of positive charge in VIP 16gamma-glutamyl diamino derivatives on hVPAC1 and hVPAC2 receptor function.
Journal of peptide science : an official publication of the European Peptide Society 2008;14(1):102-9.
2007: Langer I; Robberecht P
Molecular mechanisms involved in vasoactive intestinal peptide receptor activation and regulation: current knowledge, similarities to and differences from the A family of G-protein-coupled receptors.
Biochemical Society transactions 2007;35(Pt 4):724-8.
2006: Nachtergael Ingrid; Gaspard Nathalie; Langlet Christelle; Robberecht Patrick; Langer Ingrid
Asn229 in the third helix of VPAC1 receptor is essential for receptor activation but not for receptor phosphorylation and internalization: comparison with Asn216 in VPAC2 receptor.
Cellular signalling 2006;18(12):2121-30.
2006: Langer Ingrid; Gaspard Nathalie; Robberecht Patrick
Pharmacological properties of Chinese hamster ovary cells coexpressing two vasoactive intestinal peptide receptors (hVPAC1 and hVPAC2).
British journal of pharmacology 2006;148(8):1051-9.
2006: Langlet Christelle; Nachtergael Ingrid; Robberecht Patrick; Langer Ingrid
Mutation of the phosphorylatable residue Thr429 in Glu of the human VPAC1 led to a constitutively desensitized receptor.
Peptides 2006;27(7):1865-70.
2005: Xu Luo; Depoortere Inge; Vertongen Pascale; Waelbroeck Magali; Robberecht Patrick; Peeters Theo L
Motilin and erythromycin-A share a common binding site in the third transmembrane segment of the motilin receptor.
Biochemical pharmacology 2005;70(6):879-87.
2005: Langlet Christelle; Langer Ingrid; Vertongen Pascale; Gaspard Nathalie; Vanderwinden Jean-Marie; Robberecht Patrick
Contribution of the carboxyl terminus of the VPAC1 receptor to agonist-induced receptor phosphorylation, internalization, and recycling.
The Journal of biological chemistry 2005;280(30):28034-43.
2005: Thielemans Leen; Depoortere Inge; Perret Jason; Robberecht Patrick; Liu Yaoquan; Thijs Theo; Carreras Chris; Burgeon Emmanuel; Peeters Theo L
Desensitization of the human motilin receptor by motilides.
The Journal of pharmacology and experimental therapeutics 2005;313(3):1397-405.
2005: Langer Ingrid; Langlet Christelle; Robberecht Patrick
Effect of inactivating mutations on phosphorylation and internalization of the human VPAC2 receptor.
Journal of molecular endocrinology 2005;34(2):405-14.
2005: De Vriese Carine; Grégoire Françoise; De Neef Philippe; Robberecht Patrick; Delporte Christine
Ghrelin is produced by the human erythroleukemic HEL cell line and involved in an autocrine pathway leading to cell proliferation.
Endocrinology 2005;146(3):1514-22.
2005: Migeotte Isabelle; Riboldi Elena; Franssen Jean-Denis; Grégoire Françoise; Loison Cécile; Wittamer Valérie; Detheux Michel; Robberecht Patrick; Costagliola Sabine; Vassart Gilbert; Sozzani Silvano; Parmentier Marc; Communi David
Identification and characterization of an endogenous chemotactic ligand specific for FPRL2.
The Journal of experimental medicine 2005;201(1):83-93.
2005: Langer Ingrid; Robberecht Patrick
Mutations in the carboxy-terminus of the third intracellular loop of the human recombinant VPAC1 receptor impair VIP-stimulated [Ca2+]i increase but not adenylate cyclase stimulation.
Cellular signalling 2005;17(1):17-24.
2004: Langlet Christelle; Gaspard Nathalie; Nachtergael Ingrid; Robberecht Patrick; Langer Ingrid
Comparative efficacy of VIP and analogs on activation and internalization of the recombinant VPAC2 receptor expressed in CHO cells.
Peptides 2004;25(12):2079-86.
2004: Vertongen Pascale; Langlet Christelle; Langer Ingrid; Gaspard Nathalie; Robberecht Patrick
Ac His1 [D-Phe2, K15, R16, L27] VIP (3-7)/GRF (8-27)--a VPAC1 receptor antagonist--is an inverse agonist on two constitutively active truncated VPAC1 receptors.
Peptides 2004;25(11):1943-9.
2004: De Vriese Carine; Gregoire Francoise; Lema-Kisoka Roger; Waelbroeck Magali; Robberecht Patrick; Delporte Christine
Ghrelin degradation by serum and tissue homogenates: identification of the cleavage sites.
Endocrinology 2004;145(11):4997-5005.
2004: Van Craenenbroeck Mélanie; Gregoire Françoise; De Neef Philippe; Robberecht Patrick; Perret Jason
Ala-scan of ghrelin (1-14): interaction with the recombinant human ghrelin receptor.
Peptides 2004;25(6):959-65.
2004: Costagliola Anna; De Man Joris G; Majewski Mariusz; Lakomy Mirek; Cecio Aldo; Robberecht Patrick; Pelckmans Paul A; Adriaensen Dirk; Timmermans Jean-Pierre
Coexistence of non-adrenergic non-cholinergic inhibitory and excitatory neurotransmitters in a large neuronal subpopulation in the vaginal segment of the chicken oviduct.
Autonomic neuroscience : basic & clinical 2004;112(1-2):37-48.
2004: Wittamer Valérie; Grégoire Françoise; Robberecht Patrick; Vassart Gilbert; Communi David; Parmentier Marc
The C-terminal nonapeptide of mature chemerin activates the chemerin receptor with low nanomolar potency.
The Journal of biological chemistry 2004;279(11):9956-62.
2004: Langer Ingrid; Gregoire Françoise; Nachtergael Ingrid; De Neef Philippe; Vertongen Pascale; Robberecht Patrick
Hexanoylation of a VPAC2 receptor-preferring ligand markedly increased its selectivity and potency.
Peptides 2004;25(2):275-8.
2003: Depoortere Inge; Thijs Theo; Thielemans Leen; Robberecht Patrick; Peeters Theo L
Interaction of the growth hormone-releasing peptides ghrelin and growth hormone-releasing peptide-6 with the motilin receptor in the rabbit gastric antrum.
The Journal of pharmacology and experimental therapeutics 2003;305(2):660-7.
2003: Nachtergael Ingrid; Vertongen Pascale; Langer Ingrid; Perret Jason; Robberecht Patrick; Waelbroeck Magali
Evidence for a direct interaction between the Thr11 residue of vasoactive intestinal polypeptide and Tyr184 located in the first extracellular loop of the VPAC2 receptor.
The Biochemical journal 2003;370(Pt 3):1003-9.
2003: Langer I; Vertongen P; Perret J; Waelbroeck M; Robberecht P
Lysine 195 and aspartate 196 in the first extracellular loop of the VPAC1 receptor are essential for high affinity binding of agonists but not of antagonists.
Neuropharmacology 2003;44(1):125-31.
2002: Langer I; Vertongen P; Perret J; Waelbroeck M; Robberecht P
A small sequence in the third intracellular loop of the VPAC(1) receptor is responsible for its efficient coupling to the calcium effector.
Biochemical Society transactions 2002;30(4):447-50.
2002: Waelbroeck M; Perret J; Vertongen P; Van Craenenbroeck M; Robberecht P
Identification of secretin, vasoactive intestinal peptide and glucagon binding sites: from chimaeric receptors to point mutations.
Biochemical Society transactions 2002;30(4):437-41.
2002: Fagny Christine; Vandevelde Michel; Svoboda Michal; Robberecht Patrick
Ribonucleotide reductase and thymidine phosphorylation: two potential targets of azodicarbonamide.
Biochemical pharmacology 2002;64(3):451-6.
2002: Perret J; Vertongen P; Solano R M; Langer I; Cnudde J; Robberecht P; Waelbroeck M
Two tyrosine residues in the first transmembrane helix of the human vasoactive intestinal peptide receptors play a role in supporting the active conformation.
British journal of pharmacology 2002;136(7):1042-8.
2002: Langer Ingrid; Vertongen Pascale; Perret Jason; Cnudde Johnny; Gregoire Françoise; De Neef Philippe; Robberecht Patrick; Waelbroeck Magali
VPAC(1) receptors have different agonist efficacy profiles on membrane and intact cells.
Cellular signalling 2002;14(8):689-94.
2002: De Maria Salvatore; Metafora Salvatore; Metafora Vittoria; Morelli Francesco; Robberecht Patrick; Waelbroeck Magalì; Stiuso Paola; De Rosa Alfredo; Cozzolino Anna; Esposito Carla; Facchiano Angelo; Cartenì Maria
Transglutaminase-mediated polyamination of vasoactive intestinal peptide (VIP) Gln16 residue modulates VIP/PACAP receptor activity.
European journal of biochemistry / FEBS 2002;269(13):3211-9.
2002: Langer Ingrid; Vertongen Pascale; Perret Jason; Waelbroeck Magali; Robberecht Patrick
A small sequence in the third intracellular loop of the VPAC(1) receptor is responsible for its efficient coupling to the calcium effector.
Molecular endocrinology (Baltimore, Md.) 2002;16(5):1089-96.
2002: Perret Jason; Van Craenenbroeck Mélanie; Langer Ingrid; Vertongen Pascale; Gregoire Françoise; Robberecht Patrick; Waelbroeck Magali
Mutational analysis of the glucagon receptor: similarities with the vasoactive intestinal peptide (VIP)/pituitary adenylate cyclase-activating peptide (PACAP)/secretin receptors for recognition of the ligand's third residue.
The Biochemical journal 2002;362(Pt 2):389-94.
2001: Lema-Kisoka R; Hayez N; Langer I; Robberecht P; Sariban E; Delporte C
Characterization of functional VIP/PACAP receptors in the human erythroleukemic HEL cell line.
Peptides 2001;22(12):2155-62.
2001: Juarranz M G; Bolaños O; Gutiérrez-Cañas I; Lerner E A; Robberecht P; Carmena M J; Prieto J C; Rodríguez-Henche N
Neuroendocrine differentiation of the LNCaP prostate cancer cell line maintains the expression and function of VIP and PACAP receptors.
Cellular signalling 2001;13(12):887-94.
2001: Langer I; Perret J; Vertongen P; Waelbroeck M; Robberecht P
Vasoactive intestinal peptide (VIP) stimulates [Ca2+]i and cyclic AMPin CHO cells expressing Galpha16.
Cell calcium 2001;30(4):229-34.
2001: Dahma H; Gourlet P; Vandermeers A; Vandermeers-Piret M C; Robberecht P
Evidence that the chromogranin B fragment 368-417 extracted from a pheochromocytoma is phosphorylated.
Peptides 2001;22(9):1491-9.
2001: Vertongen P; Solano R M; Juarranz M G; Perret J; Waelbroeck M; Robberecht P
Proline residue 280 in the second extracellular loop (EC2) of the VPAC2 receptor is essential for the receptor structure.
Peptides 2001;22(9):1363-70.
2001: Vertongen P; Solano R M; Perret J; Langer I; Robberecht P; Waelbroeck M
Mutational analysis of the human vasoactive intestinal peptide receptor subtype VPAC(2): role of basic residues in the second transmembrane helix.
British journal of pharmacology 2001;133(8):1249-54.
2001: Solano R M; Langer I; Perret J; Vertongen P; Juarranz M G; Robberecht P; Waelbroeck M
Two basic residues of the h-VPAC1 receptor second transmembrane helix are essential for ligand binding and signal transduction.
The Journal of biological chemistry 2001;276(2):1084-8.
2000: Moreno D; Gourlet P; De Neef P; Cnudde J; Waelbroeck M; Robberecht P
Development of selective agonists and antagonists for the human vasoactive intestinal polypeptide VPAC(2) receptor.
Peptides 2000;21(10):1543-9.
2000: Langer I; Atassi G; Robberecht P; Résibois A
Eriochrome Black T inhibits endothelial cell growth through S-phase blockade.
European journal of pharmacology 2000;399(2-3):85-90.
2000: Vandermeers-Piret M C; Vandermeers A; Gourlet P; Ali M H; Waelbroeck M; Robberecht P
Evidence that the lizard helospectin peptides are O-glycosylated.
European journal of biochemistry / FEBS 2000;267(14):4556-60.
2000: Van Rampelbergh J; Juarranz M G; Perret J; Bondue A; Solano R M; Delporte C; De Neef P; Robberecht P; Waelbroeck M
Characterization of a novel VPAC(1) selective agonist and identification of the receptor domains implicated in the carboxyl-terminal peptide recognition.
British journal of pharmacology 2000;130(4):819-26.
2000: Juarranz M G; Van Rampelbergh J; Gourlet P; Waelbroeck M; Robberecht P
Different domains of the VIP receptors modulate agonist affinity and intrinsic activity.
Annals of the New York Academy of Sciences 2000;921():395-9.
2000: Robberecht P; Di Paolo E; Moguilevsky N; Bollen A; Waelbroeck M
Sequences (103-110) and (116-120) of the rat secretin receptor are implicated in secretin and VIP recognition.
Annals of the New York Academy of Sciences 2000;921():362-5.
1999: Juarranz M G; Van Rampelbergh J; Gourlet P; De Neef P; Cnudde J; Robberecht P; Waelbroeck M
Different vasoactive intestinal polypeptide receptor domains are involved in the selective recognition of two VPAC(2)-selective ligands.
Molecular pharmacology 1999;56(6):1280-7.
1999: Forgeur A; Willems F; Winand J; Robberecht P; Delporte C
Natriuretic peptide receptors of type A in human neuroblastomas.
Neuroendocrinology 1999;70(4):288-94.
1999: Juarranz M G; Van Rampelbergh J; Gourlet P; De Neef P; Cnudde J; Robberecht P; Waelbroeck M
Vasoactive intestinal polypeptide VPAC1 and VPAC2 receptor chimeras identify domains responsible for the specificity of ligand binding and activation.
European journal of biochemistry / FEBS 1999;265(1):449-56.
1999: Busto R; Juarranz M G; De Maria S; Robberecht P; Waelbroeck M
Evidence for multiple rat VPAC1 receptor states with different affinities for agonists.
Cellular signalling 1999;11(9):691-6.
1999: Juarranz M G; De Neef P; Robberecht P
Vasoactive intestinal polypeptide receptor VPAC(1) subtype is predominant in rat prostate membranes.
The Prostate 1999;41(1):1-6.
1999: Di Paolo E; De Neef P; Moguilevsky N; Petry H; Cnudde J; Bollen A; Waelbroeck M; Robberecht P
Properties of a recombinant human secretin receptor: a comparison with the rat and rabbit receptors.
Pancreas 1999;19(1):51-5.
1999: Forgeur A; Svoboda M; Winand J; Robberecht P; Delporte C
Human A-type ANP receptor upregulation by PACAP and carbachol in neuroblastoma cells.
Molecular and cellular endocrinology 1999;150(1-2):189-93.
1999: Walraevens V; Vandermeers-Piret M C; Vandermeers A; Gourlet P; Robberecht P
Isolation and primary structure of the CCI papain-like cysteine proteinases from the latex of Carica candamarcensis hook.
Biological chemistry 1999;380(4):485-8.
1999: Di Paolo E; Vilardaga J P; Petry H; Moguilevsky N; Bollen A; Robberecht P; Waelbroeck M
Role of charged amino acids conserved in the vasoactive intestinal polypeptide/secretin family of receptors on the secretin receptor functionality.
Peptides 1999;20(10):1187-93.
1999: Di Paolo E; Petry H; Moguilevsky N; Bollen A; De Neef P; Waelbroeck M; Robberecht P
Mutations of aromatic residues in the first transmembrane helix impair signalling by the secretin receptor.
Receptors & channels 1999;6(4):309-15.
1998: Vertongen P; Schiffmann S N; Gourlet P; Robberecht P
Autoradiographic visualization of the receptor subclasses for vasoactive intestinal polypeptide (VIP) in rat brain.
Annals of the New York Academy of Sciences 1998;865():412-5.
1998: Gourlet P; Vandermeers A; Van Rampelbergh J; De Neef P; Cnudde J; Waelbroeck M; Robberecht P
Analogues of VIP, helodermin, and PACAP discriminate between rat and human VIP1 and VIP2 receptors.
Annals of the New York Academy of Sciences 1998;865():247-52.
1998: Robberecht P; Waelbroeck M
A critical view of the methods for characterization of the VIP/PACAP receptor subclasses.
Annals of the New York Academy of Sciences 1998;865():157-63.
1998: Robberecht P; De Neef P; Lefebvre R A
Influence of selective VIP receptor agonists in the rat gastric fundus.
European journal of pharmacology 1998;359(1):77-80.
1998: Gourlet P; Rathé J; De Neef P; Cnudde J; Vandermeers-Piret M C; Waelbroeck M; Robberecht P
Interaction of lipophilic VIP derivatives with recombinant VIP1/PACAP and VIP2/PACAP receptors.
European journal of pharmacology 1998;354(1):105-11.
1998: Gourlet P; Vandermeers-Piret M C; Rathé J; De Neef P; Cnudde J; Robberecht P; Waelbroeck M
Vasoactive intestinal peptide modification at position 22 allows discrimination between receptor subtypes.
European journal of pharmacology 1998;348(1):95-9.
1998: Di Paolo E; De Neef P; Moguilevsky N; Petry H; Bollen A; Waelbroeck M; Robberecht P
Contribution of the second transmembrane helix of the secretin receptor to the positioning of secretin.
FEBS letters 1998;424(3):207-10.
1998: Dewit D; Gourlet P; Amraoui Z; Vertongen P; Willems F; Robberecht P; Goldman M
The vasoactive intestinal peptide analogue RO25-1553 inhibits the production of TNF and IL-12 by LPS-activated monocytes.
Immunology letters 1998;60(1):57-60.
1998: Svoboda M; Tastenoy M; De Neef P; Delporte C; Waelbroeck M; Robberecht P
Molecular cloning and in vitro properties of the recombinant rabbit secretin receptor.
Peptides 1998;19(6):1055-62.
1997: Vertongen P; De Clerck P; Fournet J C; Martelli H; Hélardot P; Devalck C; Peeters T; Sariban E; Robberecht P
Comparison between vasoactive intestinal polypeptide and pituitary adenylate cyclase activating polypeptide levels in neuroblastoma tumour tissues.
Neuropeptides 1997;31(5):409-13.
1997: Gourlet P; Vandermeers A; Robberecht P; Deschodt-Lanckman M
Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activating peptide (PACAP-27, but not PACAP-38) degradation by the neutral endopeptidase EC 3.4.24.11.
Biochemical pharmacology 1997;54(4):509-15.
1997: Van Rampelbergh J; Poloczek P; Françoys I; Delporte C; Winand J; Robberecht P; Waelbroeck M
The pituitary adenylate cyclase activating polypeptide (PACAP I) and VIP (PACAP II VIP1) receptors stimulate inositol phosphate synthesis in transfected CHO cells through interaction with different G proteins.
Biochimica et biophysica acta 1997;1357(2):249-55.
1997: Vilardaga J P; Di Paolo E; Bialek C; De Neef P; Waelbroeck M; Bollen A; Robberecht P
Mutational analysis of extracellular cysteine residues of rat secretin receptor shows that disulfide bridges are essential for receptor function.
European journal of biochemistry / FEBS 1997;246(1):173-80.
1997: Gourlet P; De Neef P; Cnudde J; Waelbroeck M; Robberecht P
In vitro properties of a high affinity selective antagonist of the VIP1 receptor.
Peptides 1997;18(10):1555-60.
1997: Vertongen P; Schiffmann S N; Gourlet P; Robberecht P
Autoradiographic visualization of the receptor subclasses for vasoactive intestinal polypeptide (VIP) in rat brain.
Peptides 1997;18(10):1547-54.
1997: Gourlet P; Vandermeers A; Vertongen P; Rathe J; De Neef P; Cnudde J; Waelbroeck M; Robberecht P
Development of high affinity selective VIP1 receptor agonists.
Peptides 1997;18(10):1539-45.
1997: Gourlet P; Vertongen P; Vandermeers A; Vandermeers-Piret M C; Rathe J; De Neef P; Waelbroeck M; Robberecht P
The long-acting vasoactive intestinal polypeptide agonist RO 25-1553 is highly selective of the VIP2 receptor subclass.
Peptides 1997;18(3):403-8.
1996: Gourlet P; Vandermeers A; Vandermeers-Piret M C; De Neef P; Waelbroeck M; Robberecht P
Effect of introduction of an arginine16 in VIP, PACAP and secretin on ligand affinity for the receptors.
Biochimica et biophysica acta 1996;1314(3):267-73.
1996: Van Rampelbergh J; Gourlet P; De Neef P; Robberecht P; Waelbroeck M
Properties of the pituitary adenylate cyclase-activating polypeptide I and II receptors, vasoactive intestinal peptide1, and chimeric amino-terminal pituitary adenylate cyclase-activating polypeptide/vasoactive intestinal peptide1 receptors: evidence for multiple receptor states.
Molecular pharmacology 1996;50(6):1596-604.
1996: Gourlet P; Vilardaga J P; De Neef P; Vandermeers A; Waelbroeck M; Bollen A; Robberecht P
Interaction of amino acid residues at positions 8-15 of secretin with the N-terminal domain of the secretin receptor.
European journal of biochemistry / FEBS 1996;239(2):349-55.
1996: Vertongen P; Delhase M; Rajas F; Trouillas J; Hooghe-Peters E; Svoboda M; Robberecht P
Pituitary adenylate cyclase-activating polypeptide/vasoactive intestinal polypeptide receptor subtypes are differently expressed in rat transplanted pituitary tumours (SMtTW) and in the normal gland.
Journal of molecular endocrinology 1996;16(3):239-48.
1996: Gourlet P; Vandermeers A; Vandermeers-Piret M C; Rathé J; De Neef P; Robberecht P
C-terminally shortened pituitary adenylate cyclase-activating peptides (PACAP) discriminate PACAP I, PACAP II-VIP1 and PACAP II-VIP2 recombinant receptors.
Regulatory peptides 1996;62(2-3):125-30.
1996: Vertongen P; Devalck C; Sariban E; De Laet M H; Martelli H; Paraf F; Hélardot P; Robberecht P
Pituitary adenylate cyclase activating peptide and its receptors are expressed in human neuroblastomas.
Journal of cellular physiology 1996;167(1):36-46.
1996: Vilardaga J P; di Paolo E; de Neef P; Waelbroeck M; Bollen A; Robberecht P
Lysine 173 residue within the first exoloop of rat secretin receptor is involved in carboxylate moiety recognition of Asp 3 in secretin.
Biochemical and biophysical research communications 1996;218(3):842-6.
1996: Gourlet P; Vilardaga J P; De Neef P; Waelbroeck M; Vandermeers A; Robberecht P
The C-terminus ends of secretin and VIP interact with the N-terminal domains of their receptors.
Peptides 1996;17(5):825-9.
1996: Robberecht P; Gourlet P; Vertongen P; Svoboda M
Characterization of the VIP receptor from SUP T1 lymphoblasts.
Advances in neuroimmunology 1996;6(1):49-57.
1995: Gourlet P; Vandermeers A; Vandermeers-Piret M C; Rathé J; De Neef P; Robberecht P
Fragments of pituitary adenylate cyclase activating polypeptide discriminate between type I and II recombinant receptors.
European journal of pharmacology 1995;287(1):7-11.
1995: Vilardaga J P; De Neef P; Di Paolo E; Bollen A; Waelbroeck M; Robberecht P
Properties of chimeric secretin and VIP receptor proteins indicate the importance of the N-terminal domain for ligand discrimination.
Biochemical and biophysical research communications 1995;211(3):885-91.
1995: Ciccarelli E; Svoboda M; De Neef P; Di Paolo E; Bollen A; Dubeaux C; Vilardaga J P; Waelbroeck M; Robberecht P
Pharmacological properties of two recombinant splice variants of the PACAP type I receptor, transfected and stably expressed in CHO cells.
European journal of pharmacology 1995;288(3):259-67.
1995: Delporte C; Poloczek P; de Neef P; Vertongen P; Ciccarelli E; Svoboda M; Herchuelz A; Winand J; Robberecht P
Pituitary adenylate cyclase activating polypeptide (PACAP) and vasoactive intestinal peptide stimulate two signaling pathways in CHO cells stably transfected with the selective type I PACAP receptor.
Molecular and cellular endocrinology 1995;107(1):71-6.
1995: Woussen-Colle M C; Gourlet P; Vandermeers A; Vandermeers-Piret M C; D'Haens J; Velkeniers B; Robberecht P
Identification of a new chromogranin B fragment (314-365) in endocrine tumors.
Peptides 1995;16(2):231-6.
1995: Vertongen P; d'Haens J; Michotte A; Velkeniers B; van Rampelbergh J; Svoboda M; Robberecht P
Expression of pituitary adenylate cyclase activating polypeptide and receptors in human brain tumors.
Peptides 1995;16(4):713-9.
1994: Svoboda M; Tastenoy M; Van Rampelbergh J; Goossens J F; De Neef P; Waelbroeck M; Robberecht P
Molecular cloning and functional characterization of a human VIP receptor from SUP-T1 lymphoblasts.
Biochemical and biophysical research communications 1994;205(3):1617-24.
1994: Ciccarelli E; Vilardaga J P; De Neef P; Di Paolo E; Waelbroeck M; Bollen A; Robberecht P
Properties of the VIP-PACAP type II receptor stably expressed in CHO cells.
Regulatory peptides 1994;54(2-3):397-407.
1994: Svoboda M; Tastenoy M; Vertongen P; Robberecht P
Relative quantitative analysis of glucagon receptor mRNA in rat tissues.
Molecular and cellular endocrinology 1994;105(2):131-7.
1994: Vertongen P; Ciccarelli E; Woussen-Colle M C; De Neef P; Robberecht P; Cauvin A
Pituitary adenylate cyclase-activating polypeptide receptors of types I and II and glucagon-like peptide-I receptors are expressed in the rat medullary carcinoma of the thyroid cell line 6/23.
Endocrinology 1994;135(4):1537-42.
1994: Hou X; Vandermeers A; Gourlet P; Vandermeers-Piret M C; Robberecht P
Structural requirements for the occupancy of rat brain PACAP receptors and adenylate cyclase activation.
Neuropharmacology 1994;33(10):1189-95.
1994: Robberecht P; De Neef P; Woussen-Colle M C; Vertongen P; De Witte O; Brotchi J
Presence of calcitonin gene-related peptide receptors coupled to adenylate cyclase in human gliomas.
Regulatory peptides 1994;52(1):53-60.
1994: Vilardaga J P; Ciccarelli E; Dubeaux C; De Neef P; Bollen A; Robberecht P
Properties and regulation of the coupling to adenylate cyclase of secretin receptors stably transfected in Chinese hamster ovary cells.
Molecular pharmacology 1994;45(5):1022-8.
1994: Nilsson S F; De Neef P; Robberecht P; Christophe J
Characterization of ocular receptors for pituitary adenylate cyclase activating polypeptide (PACAP) and their coupling to adenylate cyclase.
Experimental eye research 1994;58(4):459-67.
1994: Woussen-Colle M C; Lingier P; Vertongen P; Vandermeers-Piret M C; Vandermeers A; Robberecht P
Chromogranin A(210-301) is the major form of pancreastatin-like material in human gut extracts and endocrine tumors.
Peptides 1994;15(5):869-74.
1994: Robberecht P; Woussen-Colle M C; Vertongen P; De Neef P; Hou X; Salmon I; Brotchi J
Expression of pituitary adenylate cyclase activating polypeptide (PACAP) receptors in human glial cell tumors.
Peptides 1994;15(4):661-5.
1993: Svoboda M; Ciccarelli E; Tastenoy M; Robberecht P; Christophe J
A cDNA construct allowing the expression of rat hepatic glucagon receptors.
Biochemical and biophysical research communications 1993;192(1):135-42.
1992: Vandermeers A; Vandenborre S; Hou X; de Neef P; Robberecht P; Vandermeers-Piret M C; Christophe J
Antagonistic properties are shifted back to agonistic properties by further N-terminal shortening of pituitary adenylate-cyclase-activating peptides in human neuroblastoma NB-OK-1 cell membranes.
European journal of biochemistry / FEBS 1992;208(3):815-9.
1992: Buscail L; Cambillau C; Seva C; Scemama J L; De Neef P; Robberecht P; Christophe J; Susini C; Vaysse N
Stimulation of rat pancreatic tumoral AR4-2J cell proliferation by pituitary adenylate cyclase-activating peptide.
Gastroenterology 1992;103(3):1002-8.
1992: Robberecht P; Gourlet P; De Neef P; Woussen-Colle M C; Vandermeers-Piret M C; Vandermeers A; Christophe J
Receptor occupancy and adenylate cyclase activation in AR 4-2J rat pancreatic acinar cell membranes by analogs of pituitary adenylate cyclase-activating peptides amino-terminally shortened or modified at position 1, 2, 3, 20, or 21.
Molecular pharmacology 1992;42(2):347-55.
1992: Robberecht P; Gourlet P; De Neef P; Woussen-Colle M C; Vandermeers-Piret M C; Vandermeers A; Christophe J
Structural requirements for the occupancy of pituitary adenylate-cyclase-activating-peptide (PACAP) receptors and adenylate cyclase activation in human neuroblastoma NB-OK-1 cell membranes. Discovery of PACAP(6-38) as a potent antagonist.
European journal of biochemistry / FEBS 1992;207(1):239-46.
1991: Cauvin A; Robberecht P; De Neef P; Gourlet P; Vandermeers A; Vandermeers-Piret M C; Christophe J
Properties and distribution of receptors for pituitary adenylate cyclase activating peptide (PACAP) in rat brain and spinal cord.
Regulatory peptides 1991;35(2):161-73.
1991: Robberecht P; Woussen-Colle M C; De Neef P; Gourlet P; Buscail L; Vandermeers A; Vandermeers-Piret M C; Christophe J
The two forms of the pituitary adenylate cyclase activating polypeptide (PACAP (1-27) and PACAP (1-38)) interact with distinct receptors on rat pancreatic AR 4-2J cell membranes.
FEBS letters 1991;286(1-2):133-6.
1991: Gourlet P; De Neef P; Woussen-Colle M C; Vandermeers A; Vandermeers-Piret M C; Robberecht P; Christophe J
The activation of adenylate cyclase by pituitary adenylate cyclase activating polypeptide (PACAP) via helodermin-preferring VIP receptors in human SUP-T1 lymphoblastic membranes.
Biochimica et biophysica acta 1991;1066(2):245-51.
1991: Bounjoua Y; Vandermeers A; Robberecht P; Vandermeers-Piret M C; Christophe J
Purification and amino acid sequence of vasoactive intestinal peptide, peptide histidine isoleucinamide and secretin from the ovine small intestine.
Regulatory peptides 1991;32(2):169-79.
1991: Cauvin A; De Neef P; Bastianelli E; Robberecht P; Christophe J
Variable distribution, in four rat brain areas, of the three natural forms of peptide histidine isoleucinamide: PHI(1-27)NH2, PHI-Gly, and PHV (1-42).
Neuroendocrinology 1991;53(2):190-3.
1991: Cauvin A; Buscail L; Gourlet P; De Neef P; Robberecht P; Yanaihara N; Christophe J
Comparative in vitro effects of guinea pig VIP and common VIP on liver and lung membranes from guinea pig and rat and on human lymphoblastic SUP-T1 membranes.
Peptides 1991;12(1):139-43.
1991: Gourlet P; Woussen-Colle M C; Robberecht P; de Neef P; Cauvin A; Vandermeers-Piret M C; Vandermeers A; Christophe J
Structural requirements for the binding of the pituitary adenylate-cyclase-activating peptide to receptors and adenylate-cyclase activation in pancreatic and neuronal membranes.
European journal of biochemistry / FEBS 1991;195(2):535-41.
1991: Robberecht P; Gourlet P; Cauvin A; Buscail L; De Neef P; Arimura A; Christophe J
PACAP and VIP receptors in rat liver membranes.
The American journal of physiology 1991;260(1 Pt 1):G97-102.
1991: Robberecht P
New perspectives in cardiac receptors.
Acta cardiologica 1991;46(3):291-7.
1991: Gourlet P; Robberecht P; Christophe J
Molecular characterization of helodermin-preferring VIP receptors in SUP T1 lymphoma cells: evidence for receptor glycosylation.
Journal of receptor research 1991;11(5):831-48.
1990: Gossen D; Tastenoy M; Robberecht P; Christophe J
Secretin receptors in the neuroglioma hybrid cell line NG108-15. Characterization and regulation of their expression.
European journal of biochemistry / FEBS 1990;193(1):149-54.
1990: Cauvin A; Vandermeers-Piret M C; Vandermeers A; Coussaert E; de Neef P; Robberecht P; Christophe J
Rat PHI, PHI-GLY and PHV (1-42) stimulate adenylate cyclase in six rat tissue and cell membranes.
Peptides 1990;11(5):1009-14.
1990: Buscail L; Robberecht P; DeNeef P; Bui D N; Hooghe R; Christophe J
Divergent regulation of beta 2-adrenoceptors and adenylate cyclase in the Cyc- mouse T lymphoma cell line TL2-9.
Immunobiology 1990;181(1):51-63.
1990: Cauvin A; Buscail L; Gourlet P; De Neef P; Gossen D; Arimura A; Miyata A; Coy D H; Robberecht P; Christophe J
The novel VIP-like hypothalamic polypeptide PACAP interacts with high affinity receptors in the human neuroblastoma cell line NB-OK.
Peptides 1990;11(4):773-7.
1990: Buscail L; Cauvin A; Gourlet P; Gossen D; De Neef P; Rathé J; Robberecht P; Vandermeers-Piret M C; Vandermeers A; Christophe J
Purification and amino acid sequence of vasoactive intestinal peptide, peptide histidine isoleucinamide (1-27) and secretin from the small intestine of guinea pig.
Biochimica et biophysica acta 1990;1038(3):355-9.
1990: Buscail L; Gourlet P; Cauvin A; De Neef P; Gossen D; Arimura A; Miyata A; Coy D H; Robberecht P; Christophe J
Presence of highly selective receptors for PACAP (pituitary adenylate cyclase activating peptide) in membranes from the rat pancreatic acinar cell line AR 4-2J.
FEBS letters 1990;262(1):77-81.
1990: Gossen D; Buscail L; Cauvin A; Gourlet P; De Neef P; Rathe J; Robberecht P; Vandermeers-Piret M C; Vandermeers A; Christophe J
Amino acid sequence of VIP, PHI and secretin from the rabbit small intestine.
Peptides 1990;11(1):123-8.
1990: Robberecht P; Cauvin A; Gourlet P; Christophe J
Heterogeneity of VIP receptors.
Archives internationales de pharmacodynamie et de thérapie 1990;303():51-66.
1990: Christophe J; Cauvin A; Vervisch E; Buscail L; Damien C; Abello J; Gourlet P; Robberecht P
VIP receptors in human SUP-T1 lymphoblasts.
Digestion 1990;46 Suppl 2():148-55.
1989: Cauvin A; Vandermeers A; Vandermeers-Piret M C; Robberecht P; Christophe J
Variable distribution of three molecular forms of peptide histidine isoleucinamide in rat tissues: identification of the large molecular form as peptide histidine valine-(1-42).
Endocrinology 1989;125(5):2645-55.
1989: Robberecht P; Abello J; Damien C; de Neef P; Vervisch E; Hooghe R; Christophe J
Variable stimulation of adenylate cyclase activity by vasoactive intestinal-like peptides and beta-adrenergic agonists in murine T cell lymphomas of immature, helper, and cytotoxic types.
Immunobiology 1989;179(4-5):422-31.
1989: Cauvin A; Vandermeers A; Vandermeers-Piret M C; Rathe J; Robberecht P; Christophe J
Peptide histidine isoleucinamide (PHI)-(1-27)-Gly as a new major form of PHI in the rat small intestine.
Endocrinology 1989;125(3):1296-302.
1989: Damien C; Robberecht P; Hooghe R; De Neef P; Christophe J
Decreased adenylate cyclase activation by helodermin and PGE1 in the lectin-resistant variant Wa4 of the mouse melanoma cell line B16.
Peptides 1989;10(5):1075-9.
1989: Robberecht P; De Neef P; Abello J; Damien C; Coussaert E; Christophe J
Recovery of VIP/helodermin- and prostaglandin E1-stimulated adenylate cyclase activities in desensitized SUP-T1 human lymphoblasts.
Peptides 1989;10(5):1027-31.
1989: Robberecht P; De Neef P; Gourlet P; Cauvin A; Coy D H; Christophe J
Pharmacological characterization of the novel helodermin/VIP receptor present in human SUP-T1 lymphoma cell membranes.
Regulatory peptides 1989;26(2):117-26.
1989: Robberecht P; De Neef P; Buscail L; Christophe J
The phorbol ester TPA stimulates the expression of functional beta-adrenoceptors in human T lymphoblasts Molt 3.
The Biochemical journal 1989;261(3):959-63.
1989: Abello J; Damien C; Robberecht P; Hooghe R; Vandermeers A; Vandermeers-Piret M C; Christophe J
Homologous and heterologous regulation of the helodermin/vasoactive-intestinal-peptide response in the murine radiation leukemia-virus-induced lymphoma cell line BL/VL3.
European journal of biochemistry / FEBS 1989;183(2):269-74.
1989: Abello J; Damien C; De Neef P; Tastenoy M; Hooghe R; Robberecht P; Christophe J
Properties of vasoactive-intestinal-peptide receptors and beta-adrenoceptors in the murine radiation leukemia-virus-induced lymphoma cell line BL/VL3.
European journal of biochemistry / FEBS 1989;183(2):263-7.
1989: Gossen D; Vandermeers A; Vandermeers-Piret M C; Rathé J; Cauvin A; Robberecht P; Christophe J
Isolation and primary structure of rat secretin.
Biochemical and biophysical research communications 1989;160(2):862-7.
1989: Robberecht P; De Neef P; Waelbroeck M; Tastenoy M; Christophe J
VIP and related peptides induce rapid homologous desensitization in the human lymphoma SUP T1 cell line.
Peptides 1989;10(2):441-6.
1989: Abello J; Robberecht P; Damien C; Christophe J
Desensitization and recovery of prostaglandin-stimulated adenylate cyclase activity in a murine virus-induced T lymphoma cell line BL/VL3.
Journal of receptor research 1989;9(6):451-63.
1989: Damien C; Robberecht P; Abello J; Hooghe R; Christophe J
VIP-helodermin receptors in the murine virus-induced T lymphoma cell line BL/VL3 recover less rapidly than beta-adrenoceptors after down regulation.
Journal of receptor research 1989;9(6):441-9.
1988: Scemama J L; Robberecht P; Waelbroeck M; De Neef P; Pradayrol L; Vaysse N; Christophe J
CCK and gastrin inhibit adenylate cyclase activity through a pertussis toxin-sensitive mechanism in the tumoral rat pancreatic acinar cell line AR 4-2J.
FEBS letters 1988;242(1):61-4.
1988: Svoboda M; Poloczek P; Winand J; Robberecht P; Christophe J
Species differences in the molecular characteristics of vasoactive-intestinal-peptide receptors in the pancreas from rat and guinea-pig.
European journal of biochemistry / FEBS 1988;174(1):59-66.
1988: Robberecht P; Waelbroeck M; de Neef P; Camus J C; Coy D H; Christophe J
Pharmacological characterization of VIP receptors in human lung membranes.
Peptides 1988;9(2):339-45.
1988: Robberecht P; Waelbroeck M; De Neef P; Tastenoy M; Gourlet P; Cogniaux J; Christophe J
A new type of functional VIP receptor has an affinity for helodermin in human SUP-T1 lymphoblasts.
FEBS letters 1988;228(2):351-5.
1988: Robberecht P; Vandermeers A; Vandermeers-Piret M C; Gourlet P; Cauvin A; De Neef P; Christophe J
Helodermin-like peptides.
Annals of the New York Academy of Sciences 1988;527():186-203.
1988: Waelbroeck M; Camus J; Tastenoy M; De Neef P; Scemama J L; Fourmy D; Vaysse N; Pradayrol L; Robberecht P; Christophe J
Characterization of muscarinic receptors in human pancreatic membranes.
Pancreas 1988;3(6):627-30.
1988: Waelbroeck M; Robberecht P; De Neef P; Christophe J
Effects of d-tubocurarine on rat cardiac muscarinic receptors: a comparison with gallamine.
Journal of receptor research 1988;8(6):787-808.
1988: Robberecht P; De Neef P; Waelbroeck M; Camus J C; Scemama J L; Fourmy D; Pradayrol L; Vaysse N; Christophe J
Secretin receptors in human pancreatic membranes.
Pancreas 1988;3(5):529-35.
1988: Christophe J; Svoboda M; Waelbroeck M; Winand J; Robberecht P
Vasoactive intestinal peptide receptors in pancreas and liver. Structure-function relationship.
Annals of the New York Academy of Sciences 1988;527():238-56.
1988: Robberecht P; Waelbroeck M; De Neef P; Camus J C; Gourlet P; Christophe J
Effect of freezing on the coupling of VIP receptors to adenylate cyclase in rat liver membranes.
Life sciences 1988;42(5):505-10.
1987: Vandermeers A; Gourlet P; Vandermeers-Piret M C; Cauvin A; De Neef P; Rathe J; Svoboda M; Robberecht P; Christophe J
Chemical, immunological and biological properties of peptides like vasoactive-intestinal-peptide and peptide-histidine-isoleucinamide extracted from the venom of two lizards (Heloderma horridum and Heloderma suspectum).
European journal of biochemistry / FEBS 1987;164(2):321-7.
1986: Dehaye J P; Winand J; Damien C; Gomez F; Poloczek P; Robberecht P; Vandermeers A; Vandermeers-Piret M C; Stiévenart M; Christophe J
Receptors involved in helodermin action on rat pancreatic acini.
The American journal of physiology 1986;251(5 Pt 1):G602-10.

Sign-in to see more